New Head of Development
Swedish AlzeCure Pharma AB recently appointed Cecilia Wadell as Head of Development. She joins also the management team.
Cecilia Wadell, MScPharm, Ph.D., took up her new position in August. She oversees the clinical development department of the Huddinge-based company, which specializes in Alzheimer’s and pain management. “Cecilia has extensive experience in all phases of drug development and many years of experience in management positions,” said Märta Segerdahl, Wadell’s predecessor. She will now focus on her actual role as CMO.
The new Head of the development department at AlzeCure has more than 25 years of industry experience in senior positions at both large pharmaceutical companies and smaller biotech companies, such as AstraZeneca, Wilson Therapeutics, Medivir, and World Wide Clinical Trials
Roche, Herzog&De Meuron
Confo Therapeutics NV
AC Immune SA